Resp Flashcards
Question: What are the common features of an acute asthma attack?
Answer: Common features include:
Worsening dyspnoea, wheeze, and cough not responding to salbutamol
May be triggered by a respiratory tract infection
Question: How are patients with acute severe asthma stratified?
Answer: Patients are stratified into moderate, severe, or life-threatening asthma.
Question: What are the criteria for moderate acute asthma?
Answer:
PEFR: 50-75% best or predicted
Speech: Normal
Respiratory rate (RR): < 25 / min
Pulse: < 110 bpm
Question: What are the criteria for severe acute asthma?
Answer:
PEFR: 33-50% best or predicted
Speech: Can’t complete sentences
Respiratory rate (RR): > 25 / min
Pulse: > 110 bpm
Question: What are the criteria for life-threatening asthma?
Answer:
PEFR: < 33% best or predicted
Oxygen saturation: < 92%
Signs: Silent chest, cyanosis, or feeble respiratory effort
Vital signs: Bradycardia, dysrhythmia, or hypotension
Mental status: Exhaustion, confusion, or coma
Question: What does a normal pCO2 in an acute asthma attack indicate, and how should it be classified?
Answer: A normal pCO2 in an acute asthma attack indicates exhaustion and should be classified as life-threatening.
Question: What characterizes near-fatal asthma?
Answer: Near-fatal asthma is characterized by a raised pCO2 and/or requiring mechanical ventilation with raised inflation pressures.
Question: What further assessments are recommended by the BTS guidelines for patients with oxygen sats < 92%?
Arterial blood gases should be checked.
Chest X-ray is recommended in cases of life-threatening asthma, suspected pneumothorax, or failure to respond to treatment.
Question: When should all patients with life-threatening asthma be admitted to the hospital?
Answer: All patients with life-threatening asthma should be admitted immediately.
Question: What are the criteria for admitting patients with severe acute asthma?
Failure to respond to initial treatment.
Previous near-fatal asthma attack.
Pregnancy.
Attack occurring despite already using oral corticosteroids.
Presentation at night.
Question: What is the initial oxygen therapy for hypoxaemic patients?
Start on 15L of supplemental oxygen via a non-rebreathe mask, which can then be titrated down to maintain SpO2 94-98%.
Question: What is the role of short-acting beta2-agonists (SABA) in acute asthma management?
Answer: High-dose inhaled SABA (e.g., salbutamol, terbutaline) is used for bronchodilation. Nebulised SABA is recommended for patients with features of life-threatening asthma.
Question: What corticosteroid regimen is recommended for all patients with acute asthma?
Answer: 40-50mg of prednisolone orally (PO) daily, continued for at least five days or until the patient recovers from the attack.
Question: What additional treatments are recommended for severe or life-threatening asthma?
Nebulised ipratropium bromide.
IV magnesium sulphate.
IV aminophylline (following consultation with senior medical staff).
Question: What are the criteria for discharging a patient with acute asthma?
Stable on discharge medication for 12-24 hours.
Inhaler technique checked and recorded.
PEF >75% of best or predicted.
Question: What is acute bronchitis and how long does it usually last?
Answer: Acute bronchitis is a type of chest infection resulting from inflammation of the trachea and major bronchi, often producing sputum. It is usually self-limiting and resolves before 3 weeks, although 25% of patients may have a cough beyond this time.
Question: What is the leading cause of acute bronchitis and during which seasons does it most commonly occur?
Answer: Viral infection is the leading cause of acute bronchitis, with around 80% of episodes occurring in autumn or winter.
Question: What are the typical presenting symptoms of acute bronchitis?
Cough: may or may not be productive
Sore throat
Rhinorrhoea
Wheeze
Question: What are the common physical examination findings in patients with acute bronchitis?
The majority of patients have a normal chest examination, but some may present with:
Low-grade fever
Wheeze
Question: How can you differentiate between acute bronchitis and pneumonia based on history?
Answer: In acute bronchitis, sputum, wheeze, and breathlessness may be absent, whereas in pneumonia, at least one of these symptoms tends to be present.
Question: What are the examination findings in acute bronchitis compared to pneumonia?
Answer: Acute bronchitis usually lacks other focal chest signs (e.g., dullness to percussion, crepitations, bronchial breathing) and systemic features (malaise, myalgia, fever) that are commonly present in pneumonia.
Question: What investigation is typically used to diagnose acute bronchitis?
Answer: Acute bronchitis is usually a clinical diagnosis, but CRP testing may be used if available to guide antibiotic therapy.
Question: What is the general management of acute bronchitis?
Answer:
Analgesia
Good fluid intake
Consider antibiotic therapy if the patient:
Is systemically very unwell
Has pre-existing comorbidities
Has a CRP of 20-100 mg/L (offer delayed prescription) or CRP >100 mg/L (offer antibiotics immediately)
Question: What is the first-line antibiotic recommended for acute bronchitis according to the BNF, and what are the alternatives?
Answer:
First-line: Doxycycline (not suitable for children or pregnant women)
Alternatives: Amoxicillin
Question: What are the most common bacterial causes of acute exacerbations of COPD?
Haemophilus influenzae (most common)
Streptococcus pneumoniae
Moraxella catarrhalis
Question: What are the most important respiratory viruses that cause COPD exacerbations, and what percentage do they account for?
Answer: Respiratory viruses account for around 30% of exacerbations, with human rhinovirus being the most important pathogen.
Question: What are the typical features of an acute exacerbation of COPD?
Increase in dyspnoea, cough, wheeze
Possible increase in sputum suggestive of an infective cause
Patients may be hypoxic and, in some cases, have acute confusion
Question: According to NICE guidelines from 2010, what is recommended for the management of an acute exacerbation of COPD?
Increase the frequency of bronchodilator use, consider nebuliser
Prednisolone 30 mg daily for 5 days
Antibiotics if sputum is purulent or there are clinical signs of pneumonia
First-line antibiotics: amoxicillin, clarithromycin, or doxycycline
Question: What are the admission criteria for acute exacerbations of COPD?
Severe breathlessness
Acute confusion or impaired consciousness
Cyanosis
Oxygen saturation < 90% on pulse oximetry
Social reasons (e.g., inability to cope at home)
Significant comorbidity (e.g., cardiac disease, insulin-dependent diabetes)
Question: What is the initial oxygen saturation target for COPD patients at risk of hypercapnia, and what device should be used?
An initial oxygen saturation target of 88-92% should be used. A 28% Venturi mask at 4 l/min should be used until blood gas results are available.
Question: What are the nebulised bronchodilators recommended for severe exacerbations of COPD?
Beta adrenergic agonists: e.g., salbutamol
Muscarinic antagonists: e.g., ipratropium
Question: What steroid therapy is recommended for acute exacerbations of COPD, and when might IV hydrocortisone be considered?
Prednisolone 30 mg orally daily for 5 days
IV hydrocortisone may be considered instead of oral prednisolone in some cases
Question: When might IV theophylline be considered in the management of acute exacerbations of COPD?
Answer: IV theophylline may be considered for patients not responding to nebulised bronchodilators.
Question: What type of respiratory failure are patients with COPD prone to develop, and what is a common treatment for it?
Answer: Patients with COPD are prone to develop type 2 respiratory failure. Non-invasive ventilation (NIV) may be used, typically with bilevel positive airway pressure (BiPAP).
Question: What is the primary pathological mechanism in Acute Respiratory Distress Syndrome (ARDS)?
Answer: ARDS is caused by the increased permeability of alveolar capillaries, leading to fluid accumulation in the alveoli, resulting in non-cardiogenic pulmonary oedema.
Question: What is the approximate mortality rate associated with ARDS?
Answer: The mortality rate of ARDS is around 40%.
Question: What are the common causes of ARDS?
Infection: sepsis, pneumonia
Massive blood transfusion
Trauma
Smoke inhalation
Acute pancreatitis
COVID-19
Cardio-pulmonary bypass
Question: What are the typical clinical features of ARDS?
Dyspnoea
Elevated respiratory rate
Bilateral lung crackles
Low oxygen saturations
Question: What are the key investigations for diagnosing ARDS?
Chest x-ray
Arterial blood gases (ABGs)
Question: What are the American-European Consensus Conference criteria for diagnosing ARDS?
Acute onset (within 1 week of a known risk factor)
Pulmonary oedema: bilateral infiltrates on chest x-ray (not fully explained by effusions, lobar/lung collapse, or nodules)
Non-cardiogenic: pulmonary artery wedge pressure needed if doubt
pO2/FiO2 < 40 kPa (300 mmHg)
Question: What is the general management approach for ARDS?
Oxygenation/ventilation to treat hypoxaemia
General organ support: e.g., vasopressors as needed
Treatment of the underlying cause: e.g., antibiotics for sepsis
Question: Which specific strategies have been shown to improve outcomes in ARDS?
Prone positioning
Muscle relaxation
Question: What causes Allergic Bronchopulmonary Aspergillosis (ABPA)?
Answer: ABPA results from an allergy to Aspergillus spores.
Question: What clinical history is often associated with ABPA in exam questions?
Answer: A history of bronchiectasis and eosinophilia.
Question: What are the typical features of ABPA?
Bronchoconstriction: wheeze, cough, dyspnoea (patients may have a previous diagnosis of asthma)
Bronchiectasis (proximal)
Question: What investigations are commonly conducted for ABPA?
Eosinophilia
Flitting CXR changes
Positive radioallergosorbent (RAST) test to Aspergillus
Positive IgG precipitins (not as positive as in aspergilloma)
Raised IgE
Question: What is the first-line management for ABPA?
Answer: Oral glucocorticoids
Question: What is a potential second-line agent for managing ABPA?
Answer: Itraconazole
Question: What is Alpha-1 Antitrypsin (A1AT) deficiency?
Answer: A1AT deficiency is a common inherited condition caused by a lack of a protease inhibitor normally produced by the liver. It protects cells from enzymes such as neutrophil elastase and classically causes emphysema in young, non-smoking patients.
Question: What are the features of A1AT deficiency?
Lungs: Panacinar emphysema, most marked in the lower lobes
Liver: Cirrhosis and hepatocellular carcinoma in adults, cholestasis in children
Question: What investigations are used to diagnose A1AT deficiency?
A1AT concentrations
Spirometry: Shows an obstructive pattern
Question: What are the management strategies for A1AT deficiency?
No smoking
Supportive care: Bronchodilators, physiotherapy
Intravenous alpha1-antitrypsin protein concentrates
Surgery: Lung volume reduction surgery, lung transplantation
Question: What is the threshold for hypoxaemia in ABG interpretation?
Answer: A PaO2 less than 10 kPa indicates hypoxaemia.
What are the steps in interpreting ABG
Answer: How is the patient? Assess the overall clinical condition of the patient.
Answer: Is the patient hypoxaemic? The PaO2 on air should be >10 kPa.
Answer: Is the patient acidaemic or alkalaemic? Determine if the pH is <7.35 (acidaemia) or >7.45 (alkalaemia).
Answer: Respiratory component: What has happened to the PaCO2?
Answer: Metabolic component: What is the bicarbonate level/base excess?
Question: What indicates acidaemia in ABG interpretation?
Answer: A pH less than 7.35 indicates acidaemia.
Question: What indicates alkalaemia in ABG interpretation?
Answer: A pH greater than 7.45 indicates alkalaemia.
Question: What does a PaCO2 > 6.0 kPa suggest?
Answer: A PaCO2 > 6.0 kPa suggests respiratory acidosis (or respiratory compensation for a metabolic alkalosis).
Question: What does a PaCO2 < 4.7 kPa suggest?
Answer: A PaCO2 < 4.7 kPa suggests respiratory alkalosis (or respiratory compensation for a metabolic acidosis).
Question: What does a bicarbonate level < 22 mmol/L or a base excess < -2 mmol/L suggest?
Answer: A bicarbonate level < 22 mmol/L or a base excess < -2 mmol/L suggests metabolic acidosis (or renal compensation for a respiratory alkalosis).
Question: What does a bicarbonate level > 26 mmol/L or a base excess > +2 mmol/L suggest?
Answer: A bicarbonate level > 26 mmol/L or a base excess > +2 mmol/L suggests metabolic alkalosis (or renal compensation for a respiratory acidosis).
Question: What is the most common form of asbestos-related lung disease?
Answer: Pleural plaques are the most common form of asbestos-related lung disease.
Question: Are pleural plaques malignant?
Answer: No, pleural plaques are benign and do not undergo malignant change. They do not require follow-up.
Question: How long is the latent period for pleural plaques?
Answer: The latent period for pleural plaques is typically 20-40 years after asbestos exposure.
Question: What is pleural thickening in asbestos exposure?
Answer: Pleural thickening is a condition that may occur following asbestos exposure and resembles patterns seen after empyema or haemothorax. Its pathophysiology is not fully understood.
Question: What is the typical latent period for asbestosis?
Answer: The latent period for asbestosis is typically 15-30 years.
Question: What are the common features of asbestosis?
Dyspnoea and reduced exercise tolerance
Clubbing
Bilateral end-inspiratory crackles
Restrictive pattern with reduced gas transfer on lung function tests
Question: How is asbestosis treated?
Answer: Asbestosis is treated conservatively, as no interventions offer significant benefit.
Question: What is mesothelioma?
Answer: Mesothelioma is a malignant disease of the pleura, often caused by asbestos exposure, particularly crocidolite (blue) asbestos.
Question: What are the common features of mesothelioma?
Progressive shortness of breath
Chest pain
Pleural effusion
Question: What is the prognosis for mesothelioma?
Answer: The prognosis for mesothelioma is very poor, with a median survival from diagnosis of 8-14 months.
Question: What is the most common form of cancer associated with asbestos exposure?
Answer: Lung cancer is the most common form of cancer associated with asbestos exposure.
Question: How does smoking affect the risk of lung cancer in patients exposed to asbestos?
Answer: Smoking increases the risk of lung cancer in individuals with asbestos exposure. The combination of asbestos exposure and smoking has a synergistic effect, significantly raising the risk.
Question: What is aspiration pneumonia?
Answer: Aspiration pneumonia is a pneumonia that develops as a result of foreign materials (usually oral or gastric contents) entering the bronchial tree, causing inflammation and infection.
Question: What are the common causes of aspiration pneumonia?
Common causes include:
Incompetent swallowing mechanisms (e.g., neurological diseases such as stroke, multiple sclerosis, or intoxication)
Iatrogenic causes (e.g., intubation)
Question: What are the risk factors for aspiration pneumonia?
Risk factors include:
Poor dental hygiene
Swallowing difficulties
Prolonged hospitalization or surgical procedures
Impaired consciousness
Impaired mucociliary clearance
Question: Which lung lobes are most commonly affected by aspiration pneumonia?
Answer: The right middle and lower lung lobes are most commonly affected due to the larger calibre and more vertical orientation of the right main bronchus.
Question: What types of bacteria are implicated in aspiration pneumonia?
Both aerobic and anaerobic bacteria can cause aspiration pneumonia.
Aerobic bacteria:
Streptococcus pneumoniae
Staphylococcus aureus
Haemophilus influenzae
Pseudomonas aeruginosa
Klebsiella (often seen in aspiration lobar pneumonia in alcoholics)
Anaerobic bacteria:
Bacteroides
Prevotella
Fusobacterium
Peptostreptococcus
Question: What is asthma?
Answer: Asthma is a chronic inflammatory disorder of the airways caused by type 1 hypersensitivity, leading to variable and recurring symptoms such as reversible bronchospasm, airway obstruction, and difficulty breathing.
Question: What are common risk factors for developing asthma?
Risk factors include:
Personal or family history of atopy
Maternal smoking, viral infections during pregnancy, low birth weight, not being breastfed
Exposure to allergens (e.g., house dust mite)
Air pollution and the “hygiene hypothesis”
Occupational allergens (e.g., isocyanates, flour)
Question: What are common symptoms of asthma?
Cough (often worse at night)
Dyspnoea (difficulty breathing)
Wheeze and chest tightness
Question: What are the signs of asthma on examination?
Expiratory wheeze on auscultation
Reduced peak expiratory flow rate (PEFR)
Question: How is asthma diagnosed?
Diagnosis is confirmed using spirometry which shows:
Reduced FEV1 (forced expiratory volume in 1 second)
Normal FVC (forced vital capacity)
FEV1/FVC ratio < 70%
Other tests include fractional exhaled nitric oxide (FeNO) to assess inflammation and chest x-ray for older or smoking patients.
Question: What are the main drug classes used in asthma management?
Drug classes include:
Short-acting beta-agonists (SABA) (e.g., Salbutamol) – for acute relief
Inhaled corticosteroids (ICS) (e.g., Beclometasone) – for long-term control
Long-acting beta-agonists (LABA) (e.g., Salmeterol) – for maintenance
Leukotriene receptor antagonists (e.g., Montelukast) – oral medication
Question: What is Maintenance and Reliever Therapy (MART)?
Answer: MART is a combined therapy of ICS and LABA, where a single inhaler containing both is used for both daily maintenance and symptom relief. It requires a fast-acting LABA (e.g., formoterol).
Question: What is the first-line investigation for suspected asthma in adults according to the 2024 NICE guidelines?
The first-line investigations include measuring:
Eosinophil count, or
Fractional exhaled nitric oxide (FeNO)
If eosinophil count is above the reference range or FeNO is ≥ 50 ppb, asthma can be diagnosed without further investigations.
Question: What is the diagnostic threshold for bronchodilator reversibility (BDR) in adults with suspected asthma?
Asthma is diagnosed if:
The FEV1 increase is ≥ 12% and 200 mL from the pre-bronchodilator measurement, or
The FEV1 increase is ≥ 10% of the predicted normal FEV1
Question: If spirometry is not available in adults, how can asthma be diagnosed?
If spirometry is not available or delayed, peak expiratory flow (PEF) can be measured twice daily for 2 weeks. Asthma is diagnosed if:
PEF variability (amplitude percentage mean) is ≥ 20%
Question: What is the diagnostic threshold for FeNO in children aged 5-16?
Answer: Asthma is diagnosed in children aged 5-16 if FeNO is ≥ 35 ppb.
Question: What investigations are used to diagnose asthma in children aged 5-16 if FeNO is not raised?
If FeNO is not raised or not available, the following tests are used:
Bronchodilator reversibility (BDR) with spirometry, diagnosing asthma if FEV1 increase is ≥ 12% or ≥ 10% of the predicted normal FEV1.
If spirometry is unavailable, PEF variability (≥ 20%) over 2 weeks may support diagnosis.
Skin prick testing or measuring total IgE levels to assess allergen sensitivity.
Question: How should asthma be diagnosed in children under 5 according to NICE guidelines?
In children under 5, diagnosis is challenging. The guidelines suggest:
Treating with inhaled corticosteroids and regular review.
Referral to a specialist if there are 2 or more emergency admissions with wheezing in 12 months.
Question: What role do eosinophils play in asthma?
Answer: Eosinophils are involved in type 2 inflammation, releasing cytotoxic proteins that damage epithelial cells and perpetuate inflammation. They are a key marker for disease activity in asthma.
Question: What does FeNO reflect in asthma diagnosis?
Answer: FeNO reflects the level of nitric oxide produced by airway epithelial cells in response to eosinophilic inflammation, a hallmark of asthma. It is measured non-invasively in parts per billion (ppb).
Question: What is the significance of bronchodilator reversibility (BDR) in asthma diagnosis?
Answer: BDR testing evaluates the reversibility of airway obstruction after bronchodilator administration. In asthma, an increase in FEV1 of ≥ 12% and ≥ 200 mL confirms reversible airway obstruction, distinguishing asthma from fixed obstruction (e.g., COPD).
Question: How does peak expiratory flow (PEF) variability help diagnose asthma?
Answer: PEF variability reflects diurnal changes in airway calibre due to underlying inflammation and smooth muscle tone. A ≥ 20% variation in PEF between morning and evening supports the diagnosis of asthma.
Question: What is the role of skin prick testing in diagnosing asthma in children?
Answer: Skin prick testing for house dust mite is used to identify sensitisation to common allergens, such as house dust mite, which may trigger asthma. Sensitisation supports the diagnosis of allergic asthma.
Question: What is the bronchial challenge test used for in asthma diagnosis?
Answer: The bronchial challenge test assesses airway hyperresponsiveness by exposing the airways to a provocative agent (e.g., methacholine or histamine). A significant decline in FEV1 indicates asthma.
Question: What is the first-line treatment for newly diagnosed asthma in adults aged ≥12 according to the 2024 NICE guidelines?
Answer: The first-line treatment is a low-dose inhaled corticosteroid (ICS)/formoterol combination inhaler to be taken as needed for symptom relief. This is known as anti-inflammatory reliever (AIR) therapy.
Question: What is the recommended treatment for a patient with newly diagnosed asthma who presents with severe exacerbation or highly symptomatic (e.g., regular nocturnal waking)?
Answer: For such patients, start treatment with low-dose Maintenance and Reliever Therapy (MART), which includes a combination of ICS/formoterol for daily maintenance and as needed for symptom relief. Acute symptoms may also require oral corticosteroids.
Question: What does Maintenance and Reliever Therapy (MART) consist of?
Answer: MART involves using a combination inhaler containing ICS and formoterol for both daily maintenance therapy and the relief of symptoms as needed, i.e., regularly and as required.
Question: How is asthma management escalated to Step 3 in adults according to the NICE guidelines?
Answer: In Step 3, the treatment involves a moderate-dose MART, which is a combination of ICS and formoterol at a higher dose.
Question: What should be done at Step 4 if asthma control is inadequate despite moderate-dose MART?
Answer: At Step 4, check fractional exhaled nitric oxide (FeNO) and blood eosinophil count. If either is raised, refer to a specialist. If neither is raised, trial either a leukotriene receptor antagonist (LTRA) or a long-acting muscarinic antagonist (LAMA) alongside moderate-dose MART. If control does not improve, switch to the alternative treatment (LTRA or LAMA).
Question: What is the recommended action if asthma control is still not achieved at Step 5 despite treatment?
Answer: Refer the patient to a specialist in asthma care if asthma is not controlled despite treatment with moderate-dose MART and trials of LTRA or LAMA.
Question: What is the recommended treatment for adults with asthma who were previously managed with SABA as required only?
Answer: Switch the patient to a low-dose ICS/formoterol combination inhaler used as needed, which is now termed anti-inflammatory reliever (AIR) therapy.
Question: How should patients previously managed with SABA and regular low-dose ICS or LABA be treated according to the new guidelines?
Answer: These patients should be transitioned to a regular low-dose ICS/formoterol combination inhaler as Maintenance and Reliever Therapy (MART).
Question: What is the recommended treatment for patients previously managed with moderate-dose ICS and other add-ons like LTRA or LAMA?
Answer: These patients should be transitioned to a regular moderate-dose ICS/formoterol combination inhaler as part of MART therapy.
Question: What should be done for patients currently on high-dose ICS for asthma management?
Answer: Patients on high-dose ICS should be referred to a respiratory specialist.
Question: What symptoms may suggest that a patient’s asthma is related to their occupation?
Answer: Symptoms may worsen at work and improve on weekends or when away from work. Patients may also report concerns that chemicals or substances at work are exacerbating their asthma.
Question: What are some common chemicals associated with occupational asthma?
Chemicals commonly associated with occupational asthma include:
Isocyanates (most common cause)
Platinum salts
Soldering flux resin
Glutaraldehyde
Flour
Epoxy resins
Proteolytic enzymes
Question: Which occupations are at higher risk for occupational asthma due to isocyanate exposure?
Answer: Occupations at higher risk include spray painting and foam moulding using adhesives, where isocyanates are commonly used.
Question: How can occupational asthma be investigated?
Answer: Serial measurements of peak expiratory flow (PEF) are recommended to be taken both at work and away from work to assess variability and identify patterns related to the workplace.
Question: How often should asthma treatment be stepped down, according to the British Thoracic Society (BTS) guidelines?
Answer: Asthma treatment should be considered for stepping down every 3 months, or more frequently if the patient has had recent treatment escalation.
Question: What factors should be considered when stepping down asthma treatment?
Duration of treatment
Side effects of treatment
Patient preference
Question: When reducing the dose of inhaled steroids, what is the recommended decrease according to the BTS guidelines?
Answer: The recommended decrease in inhaled steroids is 25-50% at a time.
Question: How often should stable asthma patients be formally reviewed?
Answer: Stable asthma patients should be formally reviewed on an annual basis, although more frequent reviews may be needed after recent treatment escalation.
Question: What is atelectasis?
Answer: Atelectasis is a common postoperative complication where basal alveolar collapse leads to respiratory difficulty, often caused by airway obstruction due to bronchial secretions.
Question: When should atelectasis be suspected in a postoperative patient?
Answer: Atelectasis should be suspected when a patient presents with dyspnoea and hypoxaemia around 72 hours postoperatively.
Question: What is the management for atelectasis?
Positioning the patient upright
Chest physiotherapy, including breathing exercises
Question: What are the most common causes of bilateral hilar lymphadenopathy?
Sarcoidosis
Tuberculosis
Question: What are other causes of bilateral hilar lymphadenopathy?
Lymphoma or other malignancies
Pneumoconiosis (e.g., berylliosis)
Fungal infections (e.g., histoplasmosis, coccidioidomycosis)
Question: What are the key features of bronchiectasis?
Persistent productive cough with large volumes of sputum
Dyspnoea
Haemoptysis
Question: What signs might be observed in a patient with bronchiectasis?
Signs include:
Abnormal chest auscultation
Coarse crackles
Wheeze
Clubbing (may be present)
Question: What are the key management strategies for bronchiectasis after assessing for treatable causes?
Physical training (e.g. inspiratory muscle training)
Postural drainage
Antibiotics for exacerbations and long-term rotating antibiotics in severe cases
Bronchodilators in selected cases
Immunisations
Surgery in selected cases (e.g., localized disease)
Question: What are the most common organisms isolated from patients with bronchiectasis?
Haemophilus influenzae (most common)
Pseudomonas aeruginosa
Klebsiella spp.
Streptococcus pneumoniae
Question: What are the common indications for chest drain insertion?
Pleural effusion
Pneumothorax (not suitable for conservative management or aspiration)
Empyema
Haemothorax
Haemopneumothorax
Chylothorax
Some cases of penetrating chest wall injury in ventilated patients
Question: What are the relative contraindications for chest drain insertion?
INR > 1.3
Platelet count < 75
Pulmonary bullae
Pleural adhesions
Question: What is the recommended positioning for a patient undergoing chest drain insertion?
The patient should be positioned:
In a supine position or at a 45º angle
Forearm behind the head for easy axillary access
Use ultrasound guidance to determine the optimal position, especially for fluid within the pleura
Question: What are the complications that may occur during chest drain insertion?
Failure of insertion (e.g., drain in wrong position)
Bleeding (around the site or into the pleural space)
Infection
Penetration of the lung
Re-expansion pulmonary oedema
Question: How is re-expansion pulmonary oedema managed after chest drain insertion?
If re-expansion pulmonary oedema is suspected:
Clamp the chest drain
Obtain an urgent chest x-ray
To prevent, avoid rapid fluid output (e.g., no more than 1L in less than 6 hours)
Question: When should a chest drain be removed in cases of fluid drainage or pneumothorax?
For fluid drainage: Remove the drain after >24 hours of no output and imaging showing resolution of fluid.
For pneumothorax: Remove when no bubbling is seen and imaging shows resolution.
Question: What are the key features of the ‘safe triangle’ for chest drain insertion?
The ‘safe triangle’ for chest drain insertion is located:
In the mid-axillary line at the 5th intercostal space.
Bordered by:
Anterior edge of the latissimus dorsi
Lateral border of the pectoralis major
A line superior to the horizontal level of the nipple
Apex below the axilla
Question: What are the general guidelines for choosing the size of the chest drain based on the indication?
Large bore chest drains are preferred for trauma and haemothorax drainage.
Smaller diameter chest drains are used for pneumothorax or pleural effusion drainage.
Question: What are the main differential diagnoses for a cavitating lung lesion on a chest x-ray?
Abscess (e.g., Staphylococcus aureus, Klebsiella, Pseudomonas)
Squamous cell lung cancer
Tuberculosis
Wegener’s granulomatosis
Pulmonary embolism
Rheumatoid arthritis
Fungal infections (e.g., Aspergillosis, Histoplasmosis, Coccidioidomycosis)
Question: Which bacterial organisms are commonly associated with lung abscesses causing cavitating lesions?
Staphylococcus aureus
Klebsiella
Pseudomonas
Question: Which types of cancer may present with cavitating lung lesions?
Answer: Squamous cell lung cancer can present with cavitating lung lesions on a chest x-ray.
Question: What is the relevance of tuberculosis in cavitating lung lesions?
Answer: Tuberculosis can lead to cavitating lung lesions, which can be detected on a chest x-ray.
Question: How does Wegener’s granulomatosis present on a chest x-ray?
Answer: Wegener’s granulomatosis can present with cavitating lung lesions on a chest x-ray due to granulomatous inflammation in the lungs.
Question: What role does rheumatoid arthritis play in cavitating lung lesions?
Answer: Rheumatoid arthritis can cause cavitating lung lesions, especially in the context of rheumatoid nodules or associated interstitial lung disease.
Question: Which fungal infections can lead to cavitating lung lesions?
Answer: Fungal infections such as Aspergillosis, Histoplasmosis, and Coccidioidomycosis can cause cavitating lung lesions.
Question: What are the common causes of lobar collapse on a chest x-ray?
Lung cancer (most common cause in older adults)
Asthma (due to mucous plugging)
Foreign body
Question: What are the general signs of lobar collapse on a chest x-ray?
Tracheal deviation towards the side of the collapse
Mediastinal shift towards the side of the collapse
Elevation of the hemidiaphragm